2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting
Copenhagen — May 20, 2021 — 2cureX announces that the outcome of the clinical trial (NCT03251612, TICC) is published by ASCO prior to its Annual Meeting in June 2021. The primary endpoint of the trial was met.The patients enrolled in the trial suffered from end stage metastatic colorectal cancer and had IndiTreat®-guided third line treatment selected from a panel of 15 drug regimen. They comprised standard cytostatics and other cancer drugs with proven effect in clinical trials. The primary endpoint was Progression Free Survival (PFS)